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Kaposi sarcoma is a tumor consisting of Kaposi sarcoma herpesvirus (KSHV)–infected tumor cells that express
endothelial cell (EC) markers and viral genes like v-cyclin, vFLIP, and LANA. Despite a strong link between KSHV
infection and certain neoplasms, de novo virus infection of human primary cells does not readily lead to cellular
transformation. We have studied the consequences of expression of v-cyclin in primary and immortalized human
dermal microvascular ECs. We show that v-cyclin, which is a homolog of cellular D-type cyclins, induces replicative stress
in ECs, which leads to senescence and activation of the DNA damage response. We find that antiproliferative
checkpoints are activated upon KSHV infection of ECs, and in early-stage but not late-stage lesions of clinical Kaposi
sarcoma specimens. These are some of the first results suggesting that DNA damage checkpoint response also
functions as an anticancer barrier in virally induced cancers.
Citation: Koopal S, Furuhjelm JH, Ja ¨rviluoma A, Ja ¨a ¨maa S, Pyakurel P, et al. (2007) Viral oncogene–induced DNA damage response is activated in Kaposi sarcoma
tumorigenesis. PLoS Pathog 3(9): e140. doi:10.1371/journal.ppat.0030140
Introduction
Recent ﬁndings suggest that DNA damage checkpoints
become activated in early stages of human tumorigenesis,
leading to growth arrest or apoptosis and thereby hindering
tumor progression. Likewise, very recent reports have
indicated that oncogene-induced senescence triggered by
DNA replication stress also has a role as a tumorigenesis
barrier. DNA damage checkpoint markers like phosphory-
lated ATM and Chk2 kinases and phosphorylated histone
H2AX and p53 are activated in precancerous lesions (early
stages of tumorigenesis) of several different human cancers,
including bladder, breast, colon, and lung cancer [1,2]. These
checkpoint responses precede p53 mutations and the
appearance of gross chromosomal abnormalities. The tu-
morigenic events early in the progression of major human
cancer types activate the ATR/ATM-regulated checkpoint as a
guard against tumor progression and genetic instability.
Candidate inducers of the response include oncogenes such
as Myc [3,4], Ras [5], Cdc6 [1], Cdc25A, E2F1, or overexpressed
cyclin E [6].
Kaposi sarcoma herpesvirus (KSHV, or human herpesvirus
8 [HHV8]) is a c-2 herpesvirus implicated in all subtypes of
Kaposi sarcoma (KS), in multicentric Castleman disease, and
in primary effusion lymphoma (PEL) [7–9]. KSHV establishes
a latent infection in host cells, where only a subset of viral
genes is expressed, while viral replication is not activated [10].
KS is an angiogenic tumor that consists of proliferating
infected cells that form irregular microvascular channels and
extravasated inﬁltrating inﬂammatory cells. Tumor cells in
KS lesions are characterized by spindle-like morphology, and
they express endothelial cell (EC) markers but also have
features of other cell lineages, like macrophages and smooth
muscle cells [11–14]. In KS lesions, all tumor cells are latently
infected by KSHV and express latent genes, such as the viral
cyclin (v-cyclin), the viral FLICE inhibitory protein (vFLIP),
and the latency associated nuclear antigen (LANA). These
latent proteins are known to impinge in the regulation of the
cell cycle, cell survival, and the major tumor suppressor
pathways p53 and pRb, which suggests that they are
important for viral pathogenesis (reviewed in [15]).
v-cyclin is structurally similar to cellular D-type cyclin and
forms an active kinase complex with cellular CDK6. v-cyclin
also associates with CDK4 and CDK2, but the binding does
not lead to signiﬁcant activation of these kinases. As its
cellular counterpart, v-cyclin–CDK6 also phosphorylates pRb
and induces accelerated S-phase entry in cultured cells, but it
has a remarkably broader substrate range than the cellular D-
type cyclin–CDK4/6 complexes (reviewed in [16–18]). v-
cyclin–CDK6 is resistant to inhibition by CDK inhibitors.
Interestingly, both p27Kip1 and p21Cip1 are phosphorylated
by v-cyclin–CDK6, which leads to their inactivation [19–22].
These properties of v-cyclin suggest that it can function as an
oncogene. However, v-cyclin expression in primary cells was
shown to induce not only DNA synthesis but also a p53-
dependent growth arrest and cytokinesis defects. These
growth-restricting steps were overcome by the loss of p53,
which exposed the oncogenic potential of v-cyclin [23].
Previous reports have demonstrated that ECs are suscep-
tible to both latent and productive infection by KSHV, and
therefore represent a good model system for studies of the
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ever, the effect of KSHV infection on the growth properties
and tumorigenic conversion of infected cells has remained
obscure. In this study, we have assessed the consequences of v-
cyclin expression and de novo KSHV infection in human ECs.
Our results show that expression of v-cyclin in ECs induces
senescence and strong DNA damage response, leading to
centrosome ampliﬁcation and growth arrest. Moreover, we
have analysed the major tumor suppressor pathways upon de
novo KSHV infection of ECs, and our data indicate that
antiproliferative checkpoints are activated during the initial
stages of KSHV infection. To determine whether DNA
damage response is also associated with the development of
KS, we examined early and late KS lesions for expression of
the checkpoint markers.
Results
v-Cyclin Expression Triggers an Intra–S-Phase Arrest in
Human ECs
To analyse the consequences of v-cyclin expression in a cell
type naturally infected by KSHV, we used both primary
human dermal microvascular ECs (HDMECs) and their
telomerase (hTERT)–immortalized derivatives (hT-HDMECs).
The cells were transduced with retroviruses expressing Flag-
tagged v-cyclin protein (see Text S1 for the vectors used). To
explore the proliferation capacity of v-cyclin–expressing hT-
HDMECs (v-cyclin–ECs), freshly transduced cells were grown
for 48 h and then subjected to a 3-d selection in puromycin,
after which proliferation was analysed by an MTT assay. As
depicted in Figure 1A, cells transduced with the control virus
(vector only; mock) and nontransduced cells proliferated
during the follow-up period, while the v-cyclin–ECs did not.
The speciﬁc v-cyclin–associated kinase activity in these cells
was comparable to v-cyclin kinase activity in PEL cells, which
are naturally infected, KSHV-positive cells expressing v-
cyclin (unpublished data). However, during 2-wk culture of
the v-cyclin–ECs, v-cyclin protein was lost from the cells (as
analysed by indirect immunoﬂuorescence and Western
blotting), and the cells started to proliferate again (unpub-
lished data). For comparison, ECs transduced with a retro-
virus expressing a cellular homolog to v-cyclin, cyclin D3, had
full proliferative capacity comparable to that of the controls
(Figure 1A). Thus the proliferation arrest in the v-cyclin–ECs
was a speciﬁc property of this viral cyclin and not just a
consequence of cyclin overexpression. To examine whether
the v-cyclin–induced growth arrest in ECs was p53- depend-
ent, we transduced hT-HDMECs constitutively expressing a
dominant-negative p53 (p53CTer; encoding the C-terminal
amino acids 302–390 of murine p53). These hT-HDMECs–
p53CTer were transduced with the v-cyclin or control
retrovirus. Expression of p53CTer in the ECs disturbs the
wild-type (wt) p53 functions, which was observed as a growth
advantage over the parental hT-HDMECs (Figure 1A). Indeed,
cells coexpressing v-cyclin and p53CTer had full proliferative
capacity, suggesting that the growth arrest was p53-depend-
ent (Figure 1A).
To determine at which stage of the cell cycle v-cyclin–ECs
are arrested, we analyzed their cell-cycle proﬁle by ﬂow
cytometry 7 d after transduction. According to the DNA
proﬁle, a signiﬁcantly higher proportion of v-cyclin–ECs
were in the S-phase (36%) compared with the mock-
transduced cells (15%; Figure 1B, top panels). Similar cell-
cycle distributions were observed already at day 2 after
transduction (unpublished data). Since the v-cyclin–ECs
lacked proliferative capacity, the observed increase in the
number of S-phase cells could result either from re-
replication of nuclear DNA without subsequent mitosis
(endoreduplication) or an intra–S-phase arrest. To determine
precisely the nature of this cell-cycle arrest, we performed a
pulse-chase experiment with BrdU. A 2-h pulse of BrdU (15
lM), followed by 5-h and 10-h chase periods, was analysed by
multiparameter ﬂow cytometry. By plotting BrdU incorpo-
ration versus DNA content, we were able to detect both
BrdU-labeled and unlabeled cells. After the initial 2-h
labeling period, 10% of the mock-transduced cells and 8%
of the v-cyclin–ECs had incorporated BrdU (Figure 1B,
bottom panels). However, the total fraction of cells in S-
phase (both BrdU-positive and -negative) was higher in the v-
cyclin–ECs (24%) than in the mock ECs (10%). After the 5-h
and 10-h chase periods, the population of BrdU-positive,
mock-transduced cells had shifted towards the G2/M-phase,
while the proﬁle of BrDU-positive cells in v-cyclin–ECs
remained unchanged (unpublished data). The v-cyclin–ECs
with an S-phase DNA content but negative for BrdU
incorporation most likely represent cells that arrested at
the S-phase before the BrdU pulse. This data indicates that
the v-cyclin–ECs are not undergoing endoreduplication, but
are arrested at the S-phase.
The intra–S-phase checkpoint is activated as a result of
DNA replication stress [28]. Previous studies have demon-
strated that v-cyclin–CDK6 interacts with and phosphorylates
components of the origin recognition complex such as Orc1
and Cdc6 [29]. Recent observations have established Cdc6 as a
key replication initiation protein whose stability is increased
by CDK phosphorylation [30]. The accumulated Cdc6 binds
to the origin recognition complex, and promotes the
initiation of DNA replication [31]. To explore if v-cyclin
expression in the ECs induces premature or aberrant ﬁring of
the replication origins, we analysed the protein level of Cdc6
in the v-cyclin–ECs. v-cyclin–ECs had highly elevated levels
compared with the mock-ECs, demonstrating that v-cyclin
expression induces accumulation of the essential licensing
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Author Summary
Recent findings have indicated that DNA hyper-replication triggered
by oncogenes can induce cellular senescence, which together with
the oncogene-induced DNA damage checkpoint confers a barrier to
tumorigenesis. Kaposi sarcoma herpesvirus (KSHV) can infect human
dermal microvascular endothelial cells (ECs) in vitro, but KSHV
infection does not seem to provide growth advantage to the cells,
but rather leads to retarded growth. Moreover, the proliferative
index has long been known to be low in KSHV-infected spindle cells
in Kaposi sarcoma (KS) tumors. Our results provide an explanation
for these observations by showing that activation of the DNA
damage response, exerted by KSHV and a latent viral protein v-
cyclin, functions as a barrier against transformation of KSHV-infected
cells. Interestingly, the antiproliferative checkpoints are activated
during the initial stages of KSHV infection and KS tumorigenesis.
During the course of infection, the infected cells are imposed to
overcome the checkpoint, and oncogenic stress elicited by the
expression of v-cyclin may further contribute to the induction of
genomic instability and malignant transformation.Figure 1. v-Cyclin Expression in ECs Triggers an Intra–S-Phase Growth Arrest
(A) hT-HDMECs expressing mock, v-cyclin, or cyclin D3, and hT-HDMECs-p53CTer expressing mock (mock-p53CT) or v-cyclin (v-cyclin-p53CT) were
assayed for metabolic activity by a MTT assay at 6, 8, and 10 d after transduction. Nontransduced hT-HDMECs (no virus) were included as a control in the
assay.
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DNA Damage Response in KS Tumorigenesisfactor Cdc6 in ECs (Figure 1C). Similar accumulation of Cdc6
has also been seen in response to expression of other
oncogenes such as Mos [1].
Oncogene-induced DNA replication stress induces senes-
cence in human diploid cells [1,5]. To address whether a viral
oncogene can also induce senescence, we stained the v-
cyclin–ECs for the senescence-associated beta-galactosidase
[32,33] (see Text S1). H-RasV12–expressing ECs were used as a
positive control. Both the H-RasV12– and v-cyclin–ECs
stained positive for senescence-associated beta-galactosidase,
while the mock-transduced ECs remained negative (Figure
1D). In addition to the positive signal from the senescence
marker, the v-cyclin–ECs appeared signiﬁcantly larger and
ﬂatter than cells expressing the mock virus.
v-Cyclin Induces DNA Damage Response in ECs
In response to replication stalling and DNA damage,
checkpoint pathways are activated. We therefore analysed
whether v-cyclin expression was evoking a DNA damage
checkpoint in ECs. The occurrence of a DNA damage
response can be ascertained by monitoring the appearance
of speciﬁc markers such as phosphorylated histone H2AX (c-
H2AX), phosphorylation of the ATM kinase (on Ser1981; pS-
ATM), or Chk2 kinase (on Thr68; pT-Chk2), focal staining of
p53-binding protein 1 (53BP1), or increase in Ser15-phos-
phorylated p53 (pS-p53).
Cytological and biochemical analyses of v-cyclin–ECs (both
immortalized and primary ECs) showed strong induction of
all the above-mentioned DNA damage markers starting at 2–3
d after transduction (Figure 2 for hT-HDMECs and Figure S1
for the primary HDMECs). Although 53BP1 expression was
detected as uniform nuclear staining in the mock-virus–
transduced ECs, its signal in the v-cyclin–ECs appeared
dramatically different, and localized into bright intranuclear
foci (Figure 2A, bottom panel). These results suggested that v-
cyclin activates the ATM–Chk2 pathway in ECs. In accord-
ance with previous studies [23,34], the v-cyclin–ECs also
showed p53 stabilization and p21 induction (Figure 2B). In
contrast, little or no signal for the DNA damage markers was
detected in ECs transduced with the mock-virus (Figure 2A
and 2B) or with retrovirus expressing cyclin D3 (unpublished
data), consistent with the absence of a DNA damage response.
Quantitation of the number of cells expressing markers for
activated DNA damage response conﬁrmed a signiﬁcant
increase in their expression in the v-cyclin–ECs compared
with the mock-transduced ECs (Figure 2C). The pronounced
induction of c-H2AX and the S-phase promoting capacity
(Figure 1B and 1C) suggested that the DNA damage
checkpoint induced by v-cyclin expression was provoked by
DNA replication stress in the ECs.
Centrosome Amplification and Multinucleation in v-
Cyclin–ECs
Expression of v-cyclin in mouse embryonic ﬁbroblasts
(MEFs) has been shown to induce centrosome ampliﬁcation
[23], which prompted us to investigate whether the v-cyclin–
ECs also displayed supernumerary centrosomes. We analysed
the number of centrosomes in v-cyclin–expressing primary
HDMECs, hTERT-HDMECs, or endothelial EA.hy926 cells by
indirect immuoﬂuorescence. Anti–c-tubulin labeling of the
cells revealed centrosomal ampliﬁcation either as clustered
centrosomes in HDMECs and hT-HDMECs (Figure 3A, left
and middle panels) or as multiple centrosomes surrounding
the nucleus in EA.hy926 cells (Figure 3A, right panel).
Ampliﬁcation of centrosomes was often accompanied with
bi- or multinucleation. Quantitation of these results depicted
in Figure 3B for the hT-HDMECs shows a signiﬁcant increase
(4.2-fold) in the proportion of the v-cyclin–ECs with more
than two centrosomes.
To investigate whether abrogation of the ATM-Chk2–
dependent checkpoint would facilitate proliferation of the v-
cyclin–ECs, we treated the cells with caffeine and wortmannin
to inhibit ATM and ATR kinases (Figure 3C, left graph), or
with a speciﬁc ATM inhibitor KU-55933 (Figure 3C, right
graph). The inhibition was analysed by immunoﬂuorescence
analysis, which showed reduced phosphorylation of Chk2 as
well as reduction of focal staining of 53BP1 in the KU-55933–
treated cells. Treatment (unpublished data) with all of the
inhibitors partially rescued the centrosomal aberrations in
the v-cyclin–ECs (Figure 3C), but did not lead to an increase
in the net cell numbers (unpublished data). However,
inhibition of ATM–Chk2 by the chemical inhibitors led to
an increase in multinucleated syncytia-like cells (Figure 3C,
insert), suggesting that the S-phase arrest was released, but
this resulted in aberrant mitosis and subsequent ‘‘mitotic
catastrophe.’’
In order to explore if the centrosome ampliﬁcation in v-
cyclin–ECs was dependent on p53, we analysed the centro-
some numbers in hT-HDMECs constitutively expressing the
dominant-negative p53CTer together with v-cyclin, and
compared them with the v-cyclin–ECs. Inactivation of p53
by the C-terminal mutant led to a 40% decrease in the cells
with abnormal centrosome numbers (unpublished data),
suggesting that the ampliﬁcation of centrosomes by v-cyclin
is p53-dependent.
About one-third of the cells harboring more than two
centrosomes were either binucleated (as in Figure 3A),
multinucleated, or had micronuclei, indicating that karyoki-
nesis (nuclear division) had occurred without concomitant
cytokinesis. Yet, the proportion of cells undergoing mitosis in
the v-cyclin–ECs was very low as detected by an antibody
against serine 10–phosphorylated histone H3 (unpublished
data). Interestingly, the v-cyclin–ECs showed increased cyclin
B1–associated kinase activity when compared with the mock-
transduced cells as well as an increase in the nuclear
localization of cyclin B1 (Figure 3D and 3E). This suggests
that the cells were unable to switch off the cyclin B1 activity,
which in turn can lead the cells to aberrant mitosis
(karyokinesis).
(B) hT-HDMECs expressing mock or v-cyclin were subjected to cell-cycle analysis by BrdU incorporation and flow cytometry. The percentages of cells at
specific cell-cycle phases are indicated. The numbers represent mean values of four independent experiments.
(C) Whole-cell extracts of hT-HDMECs expressing mock or v-cyclin were resolved by SDS-PAGE (12%) and immunoblotted with antibodies against Cdc6.
Anti–b-tubulin was used as a loading control.
(D) hT-HDMECs constitutively expressing mock, v-cyclin, or H-RasV12 were grown for 7 d. Cells were fixed and stained for senescence-associated beta-
galactosidase activity.
doi:10.1371/journal.ppat.0030140.g001
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Amplification Are Dependent on CDK6
Next, we sought to determine whether CDK activity is
required for the observed DNA damage response and
centrosome ampliﬁcation in v-cyclin–ECs. To this end, we
depleted CDK2, CDK4, or CDK6 expression in EA.hy926 cells
using lentivirus-mediated RNA interference. EA.hy926 cells
stably expressing small hairpin RNA (shRNA) speciﬁc for the
above-mentioned kinases or control shRNA (Scramble) were
ﬁrst subjected to immunoblotting, which indicated very
efﬁcient downregulation (90%–95%) of the target proteins.
b-tubulin was used as a loading control for the CDK2
immunoblots (Figure 4). Silencing speciﬁcity for CDK4 and
CDK6 was controlled by reciprocal immunoblotting (i.e.,
CDK6 for CDK4 shRNA-expressing cells and vice versa;
Figure 4B).
The CDK-downregulated cells were transduced with the v-
cyclin–expressing retrovirus, and analyzed 5 d after trans-
duction for DNA damage markers and centrosome numbers
by indirect immunoﬂuorescence. Cytological analysis using
antibodies against pS-ATM and pT-Chk2 indicated that the
DNA damage response was readily activated in the control
EA.hy926 cells upon expression of v-cyclin (Figure 4A, left
panels). Depletion of CDK6 resulted in a signiﬁcant reduction
of phosphorylation on ATM and Chk2, indicating that v-
cyclin–induced DNA damage checkpoint was dependent on
CDK6 expression (Figure 4A and 4C). This is in accordance
with previous studies demonstrating that CDK6 is the in vivo
catalytic subunit of v-cyclin in the patient-derived PEL cells
[35]. Accordingly, CDK6 expression was also required for the
v-cyclin–induced centrosome ampliﬁcation (Figure 4D). In
contrast, depletion of CDK4 or CDK2 did not decrease the
DNA damage response or centrosome numbers, indicating
that v-cyclin–induced DNA damage and centrosome ampliﬁ-
cation are not dependent on either of these cyclin-dependent
kinases (Figure 4C and 4D). Interestingly, after CDK6 knock-
down, the morphology of most of the v-cyclin–ECs returns to
normal, i.e., the nuclei are of normal size and the cells do not
display a ﬂattened phenotype (Figure 4A, shCDK6 panels).
Antiproliferative Checkpoints Are Activated in KSHV-
Infected ECs
We then addressed the effects of KSHV infection on the
DNA damage response of ECs. To analyse proliferation, we
Figure 2. DNA Damage Response in v-Cyclin–ECs
(A) hT-HDMECs expressing mock (pBMNIresEGFP) or v-cyclin (KpBMNIresEGFP) retroviruses were analysed at day 5 after transduction for expression of
GFP and the indicated DNA damage markers. The labeling with anti-gamma-H2AX antibody requires EtOH fixation, which leads to a partial loss of
soluble GFP and thus reduced signal. Therefore, to allow simultaneous detection of c-H2AX together with mock or v-cyclin, the cells in these panels
were labeled also with a-GFP or a-Flag (for v-cyclin) antibodies, respectively. Scale bar ¼ 20 lm.
(B) hTERT-HDMECs expressing mock or v-cyclin at day 7 were immunoblotted with antibodies indicated on the left. c-tubulin was used as a loading
control.
(C) hT-HDMECs expressing mock or v-cyclin were analysed at day 5 by indirect immunofluorescence to determine the percentage of cells positive for
the indicated DNA damage markers. The average of two individual experiments is shown. Approximately 200 cells were analysed per sample.
doi:10.1371/journal.ppat.0030140.g002
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infecting the hT-HDMECs with a recombinant KSHV
expressing GFP (rKSHV.219 [36]). The establishment of
KSHV latent infection was conﬁrmed by immunoﬂuores-
cence using antibodies against the latent nuclear antigen,
LANA (unpublished data). Proliferation was analysed by the
MTT assay. The KSHV-ECs proliferated at a very slow rate
compared with the noninfected, passage-matched parental
Figure 3. Centrosome Amplification and Multinucleation in the v-Cyclin–ECs
(A) hT-HDMECs (left and middle panels) or EA.hy 926 cells (right panel) expressing v-cyclin were analysed for centrosomes at day 3 or 5, respectively, by
anti–c-tubulin antibody (red) and DNA by Hoechst staining (blue). Scale bar ¼ 10 lm.
(B) Quantitation of the number of centrosomes and multinuclear cells in the nontransduced (No virus), mock, or v-cyclin–expressing hT-HDMECs at day
3 after transduction. The average of two independent experiments and analysis of about 200 cells per sample is shown.
(C) Inhibition of the ATM-Chk2–dependent checkpoint decreases centrosome aberrations in v-cyclin–ECs. v-cyclin–ECs were treated with wortmannin
(200 nM) or caffeine (2 mM) 3 d after transduction for 4 h (left graph), or with KU-55933 (2 lM) 6 d after transduction for 3 d (right graph). Treated and
untreated cells were analyzed to determine the percentage of cells with activated Chk2 (by anti–pT-Chk2) or with more than two centrosomes (by anti–
c-tubulin). The average of two independent experiments is shown. More than 200 cells were analyzed per sample. Insert: inhibition of the ATM-Chk2–
dependent checkpoint in v-cyclin–ECs leads to formation of multinucleated syncytia-like cells. Scale bar ¼ 10 lm.
(D) Cell extracts of nontransduced hT-HDMECs (No virus), or hT-HDMECs expressing mock or v-cyclin for 2 d were immunoprecipitated with anti–cyclin
B1 antibodies, and subjected to in vitro kinase assay using GST-Rb and histone H1 as substrates. hTERT-HDMECs treated with nocodazole (75 ng/ml)
were used as a positive control. Kinase activity was determined by autoradiography after SDS-PAGE (12%).
(E) hT-HDMECs expressing mock or v-cyclin were labeled with a-cyclin B1 (red) and Hoechst (blue) at day 6 after transduction. Slides were
microscopically analyzed to determine the percentage of cells where cyclin B1 was excluded from the nucleus (% on the left). About 200 cells were
counted per sample. Arrows indicate cells with cyclin B1 signal excluded from the nucleus, and arrowheads indicate the cells with nuclear cyclin B1
signal. Scale bar ¼ 20 lm.
doi:10.1371/journal.ppat.0030140.g003
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were activated upon KSHV infection.
To investigate potential growth-suppressive pathways, we
took the hT-HDMEC–p53CTer, and also prepared hT-
HDMECs stably transduced with retroviruses expressing
SV40 large T antigen (hT-HDMEC-LT) or the human
papillomavirus oncogenes E6 and E7 (hT-HDMEC-E6/E7) to
abrogate the function of both the p53 and pRb tumor-
suppressor pathways. Expression of all of these genes led to a
growth advantage over the parental hT-HDMECs (Figure 5A).
After infection with KSHV, all these cell lines proliferated
faster than the KSHV-infected normal hT-HDMECs (Figure
5A), indicating that the growth arrest was overcome. The
proliferation rate was similar in cells expressing p53CTer and
those expressing the multifunctional viral oncogenes.
Although the presence of hTERT in these cells may alter
the experimental conditions, this is suggesting that the p53
pathway primarily restricted the proliferation of KSHV-ECs.
Interestingly, the KSHV-ECs started to spontaneously grow at
a faster rate approximately 3–4 wk after infection (Figure
S2A). The recovery from this crisis period was accompanied
Figure 4. v-Cyclin–Induced DNA Damage Response and Centrosome Amplification Are CDK6-Dependent
(A) shRNA-encoding EA.hy926 cells sh-Scramble or sh-CDK6 were transduced with v-cyclin retrovirus, and grown for 5 d. Transduced cells were labeled
with antibodies against pS-ATM, pT-Chk2, and Hoechst (blue) for DNA. Scale bar ¼ 20 lm.
(B) Depletion of CDK2, CDK4, or CDK6 expression in EA.hy926 cells. The cells were stably transduced with the shRNA-encoding lentiviruses targeting
either CDK2, CDK4, CDK6, or a random noncoding sequence (sh-Scr). Whole-cell extracts were resolved by SDS-PAGE (12%) and immunoblotted with
antibodies against CDK2, CDK4, CDK6, and b-tubulin.
(C) shRNA-encoding EA.hy926 cells sh-CDK2, sh-CDK4, sh-CDK6, or sh-Scr were transduced with v-cyclin retrovirus as in (A), and labeled with antibodyt o
pT-Chk2 to determine the percentage of cells with active Chk2. The average of two independent experiments with at least 200 cells analysed per
sample is shown.
(D) The sh-CDK2, sh-CDK4, sh-CDK6, or sh-Scr cells were transduced with v-cyclin retrovirus as in (A), and labeled with anti–c-tubulin antibodies and
Hoechst to analyse the centrosome numbers. The average of two independent experiments with at least 200 cells analysed per sample is shown.
doi:10.1371/journal.ppat.0030140.g004
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(Figure S2B).
A previous report [37] showed that KSHV infection of
human umbilical vein ECs (HUVECs) induced abnormal
centrosome duplication and multinucleation. We therefore
sought to determine whether centrosome aberrations oc-
curred also in our KSHV-ECs by labeling them with the c-
tubulin antibodies at 7 d after infection. This revealed that
the KSHV-infected ECs had a marked increase (.4-fold) in
the proportion of cells with more than two centrosomes
(Figure 5B, lower right panel). Furthermore, several of the
cells with ampliﬁed centrosomes were also binucleated
Figure 5. Antiproliferative Checkpoints Are Activated in KSHV-Infected ECs
(A) hT-HDMECs, hT-HDMEC–p53CTer, hT-HDMEC–LT, and hT-HDMEC–E6/E7 were infected with rKSHV.219 virus and grown for 9 d. Proliferation of these
cells in relation to noninfected cells was determined by the MTT assay at 10, 12, 14, and 16 d after infection.
(B) Top panels: KSHV-ECs grown for 7 d and stained with Hoechst. GFP is expressed from the recombinant virus. Arrows indicate binucleated cells. Scale
bar¼50 lm. Lower panels: Noninfected (No virus) and KSHV-ECs were analysed for centrosomes by anti–c-tubulin antibodies (red) and DNA by Hoechst
staining (blue) at day 7. Scale bar ¼ 5 lm.
(C) KSHV-ECs were treated with wortmannin (200 nM) or caffeine (4 mM) for 24 h, and analysed for the centrosome numbers by c-tubulin antibodies.
Untreated as well and noninfected (No virus) ECs were used as controls. Percentage of cells with aberrant centrosome numbers is shown as an average
of two independent experiments and analysis of at least 200 cells per sample.
(D) KSHV-ECs grown for 2 wk (early) or approximately 10 wk (late), and their passage-matched, noninfected ECs were labeled with anti-53BP1 antibodies
to address activation of the DNA damage response. The bar graph shows the percentage of cells with intranuclear 53BP1-positive foci. About 200 cells
were counted per sample. The insert depicts noninfected (ECs) and late KSHV-ECs showing intranuclear 53BP1 foci in the latter one (bottom right
panel). Scale bar ¼ 20 lm.
doi:10.1371/journal.ppat.0030140.g005
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DNA Damage Response in KS Tumorigenesis(Figure 5B, top two panels). Centrosome aberrations may
arise as a result of DNA damage-induced checkpoints, and
recent data indicate the involvement of the checkpoint
kinases Chk1 and Chk2 in this process (reviewed in [38,39]).
To explore the involvement of the ATM–Chk2 pathway in the
KSHV-induced centrosome ampliﬁcation, we treated the cells
with pathway inhibitors followed by analysis of the centro-
some numbers. This led to a marked decrease in the
population of cells with abnormal centrosome numbers
(Figure 5C), suggesting the involvement of the ATM–Chk2
pathway in the centrosome ampliﬁcation of KSHV-infected
ECs. We did not observe the multinucleated syncytia-like cells
as seen in the v-cyclin–ECs (Figure 3C, insert), suggesting that
expression of the other KSHV latent genes attenuated the
strong oncogenic stress elicited by v-cyclin.
Cytological analysis showed no increase in the DNA
damage markers (c-H2AX, p-ATM, pT-Chk2, 53BP1, or pS-
p53) during the growth arrest phase of KSHV-infected ECs
(early KSHV-ECs) compared with the parental noninfected
hT-HDMECs (Figure 5D). However, after overcoming the
crisis period, the proliferating KSHV-ECs (late KSHV-ECs)
displayed an increased DNA damage response as indicated by
the appearance of intranuclear 53BP1 foci (Figure 5D).
Nutlins are recently discovered small-molecule inhibitors
that competitively bind MDM2 at the p53-binding pocket and
prevent the destabilization of p53. This leads to activation of
the p53 pathway [40]. Recent results suggest that the cytotoxic
effect of Nutlin-3a in cancer cells is enhanced by intrinsic
DNA damage signaling in the cells [41], and establish the
53BP1 protein as a critical mediator of Nutlin-3a cytotoxicity
[42]. To provide further evidence of the involvement of DNA
damage signaling in KSHV infection of ECs, we treated the
proliferating, post-crisis KSHV-ECs and their parental non-
infected cells with Nutlin-3a for 24, 48, or 96 h, and analysed
them for cell viability by trypan blue exclusion. As shown in
Figure S3, Nutlin-3a treatment speciﬁcally increased apop-
tosis of KSHV-infected ECs, but had a minimal effect on the
viability of the parental noninfected cells. These data provide
additional evidence that DNA damage signaling is activated
in KSHV-infected ECs. We have recently shown that Nutlin-
3a also dissociates p53 interaction with LANA in KSHV-
infected patient-derived lymphoma cells [41], providing
evidence that p53-dependent apoptosis is restrained in
KSHV-infected cells, most probably by LANA-mediated
binding to p53. Our results from Nutlin-3a–treated KSHV-
ECs further support the fact that KSHV-infected cells cannot
proliferate or survive in the presence of active p53.
Activation of DNA Damage Response in KS Skin Lesions
Our results suggest that KSHV infection and, more
speciﬁcally, the expression of a viral latent gene can induce
the activation of DNA damage signaling. To determine
whether DNA damage response is activated in KS tumors as
it is in several human cancers and especially in premalignant
lesions [2,6], we analysed expresssion of the activated Chk2 in
early-stage (patch) and late-stage (nodular) cutaneous lesions
of KS (Figure 6). All KS lesions used in the study were
conﬁrmed for LANA expression by staining with anti-LANA
antibodies (Figure 6B and unpublished data). The early-stage
lesions are characterized by proliferating ECs forming
irregular vascular spaces, associated with extravasation of
red blood cells [43]. In the late nodular stage, the tumor
consists of bundles of spindle cells with irregular slit-like
vasculature, which is ﬁlled with erythrocytes. Immunohisto-
chemistry for pT-Chk2 showed speckled nuclear staining in
all early-stage KS skin lesions (n ¼ 5). This staining could be
blocked by a speciﬁc peptide (Figure S5). The signal was
primarily detected in the patch-like tumor islets in the dermis
(Figures 6A and S4A, top two panels), but, interestingly, it was
signiﬁcantly weaker for eight out of nine nodular KS cases (n
¼ 9; Figures 6A and S4A, bottom two panels).
The data suggested that ATM–Chk2 signaling is activated in
the early KS lesions. To expand these studies using other
DNA damage markers, we examined the phosphorylation
status of H2AX (c-H2AX) and the intranuclear localization of
53BP1, both markers of the DNA double-strand break (DSB)
checkpoint. Immunohistochemistry of early (n ¼ 3) and late
KS (n ¼ 5) lesions revealed expression of c-H2AX in both
stages (Figures 6C and S4B). However, the signal intensity in
the late-stage KS tumors was weaker than in the early KS
tumors (Figure 6C, inserts). The inﬁltrated erythrocytes,
typical for especially late-stage KS skin tumors, gave a very
prominent autoﬂuorescence signal, which is, however, easily
separatable from the speciﬁc signal due to the absence of
Hoechst staining (arrows in Figures 6C and S4B). Intriguingly,
53BP1 was mostly localized to discrete nuclear foci in the
early patch KS sections (n ¼ 4; Figure 6D, top panels), thus
resembling the DNA damage foci in irradiated cells in
culture. In two of ﬁve late-stage KS samples analyzed,
53BP1 gave a very strong but more uniform nuclear signal
(Figure 6D, bottom panels) than in the early lesions. Taken
together, the data suggests that DNA damage checkpoint is
activated especially in the early stages of KS tumorigenesis.
Discussion
The strong association between KSHV infection and
development of KS, PEL, and multicentric Castleman disease
has provided compelling evidence that KSHV is a tumori-
genic virus. KSHV is well-equipped to engage important
cellular signaling pathways such as cell cycle, apoptosis,
angiogenesis, and immune evasion (reviewed in [15]). How-
ever, direct cellular transformation by KSHV in cell culture
occurs only rarely, suggesting that additional genetic alter-
ations are required for KSHV tumorigenesis. We show here
that KSHV infection does not confer a growth advantage to
endothelial cells, and that intrinsic DNA damage signaling is
activated in the KSHV-ECs. This is further supported by our
recent ﬁnding of activated DNA damage response in KSHV-
induced lymphomas (PELs; [41]). Our results suggest that the
oncogenic stress elicited by the latent viral protein v-cyclin
promotes deregulated entry into the S-phase, thereby
inducing DNA damage. The resulting checkpoint activation
leads to growth arrest and senescence in the EC. Interestingly,
overexpressed cyclin E, Cdc6, and Ras, which all share the
ability to promote unscheduled S-phase entry, have recently
been shown to induce cellular senescence and DNA damage
response due to deregulated DNA replication [1,5,6].
Activated DNA damage signaling in KSHV-infected ECs
was observed only in the proliferating ‘‘post-crisis’’ popula-
tion of cells. It is possible that in the very early stages of de
novo KSHV infection, when the cells do not grow at all, there
can be other growth-restraining mechanisms related to the
establishment of latent infection. These may initially affect v-
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DNA Damage Response in KS Tumorigenesiscyclin function and thereby suppress the activation of the
DNA damage checkpoint. Although the KSHV-ECs start to
proliferate after overcoming the growth arrest, they still grow
slower than noninfected cells. This is accompanied by
induction of markers for the activated DNA damage
checkpoint. The induction of these markers was less
pronounced in KSHV-infected ECs than in the v-cyclin–
ECs, which may be due to expression of other latent KSHV
genes, such as LANA, that can interfere with the p53 and pRb
tumor suppressor pathways [44,45]. However, inhibition of
p53 function by LANA did not seem to be sufﬁcient initially
after infection and establishment of the latency, since an
increase in the net propagation of KSHV-infected cells
required abrogation of p53 signaling. Nevertheless, the
increased proliferative potential of KSHV-infected ECs after
the initial crisis period correlated with an increase of the
LANA signal of infected cells, suggesting that p53 function
was suppressed when critical levels of LANA expression were
achieved. This underscores the importance of p53 in
constraining KSHV pathogenesis.
It is intriguing to speculate that the accumulation of the
key replication initiation protein, Cdc6, would cause un-
timely initiation of DNA replication and lead to formation of
DNA DSBs. This is supported by the strong induction of
phosphorylated ATM and Chk2 kinases in these cells along
with the positive signals from the ATM substrates, c-H2AX,
and p53 phosphorylated on Ser 15 as well as focal staining of
53BP1. On the other hand, it is possible that v-cyclin
deregulates cellular DNA replication or simply mimics DSBs
by upregulating certain cellular factor(s) involved in the DNA
damage pathway. There is growing evidence that several DNA
viruses especially trigger DNA damage response in infected
cells [46]. In most cases, the DNA damage response is involved
in viral replication processes, and therefore the viruses have
developed ways to inhibit or circumvent the host cell [47].
Human cytomegalovirus has been shown to mislocalize ATM,
ATR, and Chk1 to limit the function of DNA repair proteins
Figure 6. DNA Damage Response Is Activated in Early-Stage KS Lesions
(A) Paraffin-embedded sections of early-stage (Patch) and late-stage (Nodular) KS skin tumors were stained for pT-Chk2, and nuclei were counterstained
with Hoechst 33342. Images were captured at 403 magnification.
(B) An early, patch-stage KS lesion stained for LANA and pT-Chk2, and counterstained with Hoechst 33342. Images were captured at 633magnification,
and represent consecutive sections. Arrows indicate nuclear, punctate LANA staining, and arrowheads indicate the pT-Chk2–positive nuclei also
displaying a nuclear, punctate signal.
(C) Early-stage (Patch) and late-stage (Nodular) KS skin lesions were stained for c-H2AX, and nuclei were counterstained with Hoechst 33342. Arrows
indicate infiltrated red blood cells. Images were captured at 403 magnification.
(D) Early-stage (Patch) and late-stage (Nodular) KS lesions were stained for 53BP1, and nuclei were counterstained with Hoechst 33342. Images were
captured at 633 magnification. Scale bars in all panels ¼ 50 lM.
doi:10.1371/journal.ppat.0030140.g006
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DNA Damage Response in KS Tumorigenesis[48]. Interestingly, recent reports identify activated DNA
damage signaling as an important mechanism both in
Epstein-Barr virus lytic replication [49] and in Epstein-Barr
virus oncogenesis [48].
Chk2 is normally activated as a result of DNA damage to
arrest the cell cycle. It functions as an effector kinase, and
prevents the activation of the cyclin B1–CDK1 complex
required for the entry into mitosis. Inhibition of Chk2 and
checkpoint signaling in the growth-arrested v-cyclin–ECs by
treatment with chemical inhibitors induced mitotic defects
(syncytia formation) and concomitant cell death (unpublished
data). This together with the increased cyclin B1–CDK1
activity in v-cyclin–ECs suggest that v-cyclin was capable of
eliciting also mitotic signals, but in the absence of activated
Chk2, v-cyclin–induced signaling resulted in mitotic catas-
trophe. This is consistent with the previously identiﬁed role
of Chk2 as the negative regulator of mitotic catastrophe [50].
In accordance with the previous ﬁndings by Verschuren
and coworkers [23] as well as Pan and colleagues [37], we
observed induction of supernumerary centrosomes and
multinucleation both by v-cyclin expression and KSHV
infection. These results suggest that, like other viral onco-
genes (E7, E1A, and LT [51]), v-cyclin can promote chromo-
somal instability by disrupting the centrosome cycle.
Abnormal, oncogene-induced centrosome duplication has
recently been shown to require CDK2 activity [52]. The v-
cyclin–induced centrosome ampliﬁcation required the v-
cyclin kinase partner CDK6, but not CDK2, which suggests
that v-cyclin–CDK6 activity may directly drive the aberrant
centrosome duplication.
Growing evidence indicates that alterations in centrosome
number or function contribute to genomic instability and
aneuploidy in advanced human cancers. Our results suggest
that v-cyclin may contribute to the centrosomal abnormal-
ities in KSHV-infected cells, which could lead to the
induction of genomic instability and thereby predispose the
cells to malignant transformation. Recently, KSHV LANA was
shown to induce centrosome aberrations and increased
multinucleation, indicating that other viral genes can also
increase the incidence of genomic instability and promote
KSHV-mediated tumorigenesis [53].
The ﬁnding of activated DNA damage signaling predom-
inantly in the early-stage KS lesions suggests that this recently
discovered anticancer barrier is also important in KS
tumorigenesis. This inducible anticancer mechanism is
activated in the premalignant lesion subject to ‘‘oncogenic
stress’’ [2,6], and it imposes a selective pressure to gain
mutations that compromise the checkpoint. The observed
checkpoint activation in the early KS lesions correlates with
their relatively low proliferation index [54] and the reduction
of apoptosis in the late-stage nodular KS lesions [55,56].
Moreover, recent analysis of chromosomal abnormalities in
KS shows increased numbers of recurrent (and sporadic)
chromosomal alterations in nodular KS compared with the
early cases [57].
We thus propose that the early steps of KSHV tumori-
genesis involve activation of the DNA damage checkpoint.
This enforces selective pressure for mutations abrogating the
checkpoint, and provides an advantage for cells with
defective DNA damage response components. KSHV v-
cyclin–induced DNA damage, particularly the DSBs, may be
one of the factors enhancing genomic instability and
progression to KS. Whether it is the DNA damage checkpoint
reported here that predominantly limits neoplastic trans-
formation by KSHV remains to be determined.
Materials and Methods
Retrovirus production and transduction. Amphotropic retrovi-
ruses were produced by transfection of Phoenix-Ampho retrovirus–
producing cells (a kind gift from G. Nolan, Stanford University,
Stanford, California, United States) with retroviral vectors using
Lipofectamine 2000 reagent (Invitrogen, http://www.invitrogen.com/).
After 48 h, viral supernatants were harvested and ﬁltered through a
0.45-lm ﬁlter (Millipore, http://www.millipore.com/), and fresh media
was added to Phoenix cells to produce more viral supernatant for a
second round of virus production for 96 h.
Target cells were plated 1 d before, and spin-transduced using 8 lg/
ml polybrene (Sigma, http://www.sigmaaldrich.com/) by centrifugation
(2500 rpm; Heraeus Multifuge 3 S-R; Thermo Scientiﬁc, http://www.
thermo.com/) for 30 min at room temperature. Cells were then
returned to 37 8C, 5% CO2, and after 1 h of incubation viral
supernatant was removed and replaced with fresh complete media.
The transduction was highly efﬁcient (80%–90%) as determined by
ﬂow cytometric analysis.
HDMECs (Promocell, http://www.promocell.com/) transduced with
pWZLblast-hTERT were subjected to blasticidin selection (5 lg/ml) 2
d after transduction. Cells transduced with pBabe, 2FkpBabe,
D3pBabe, or pBabepuro-H-RasV12 retrovirus were subjected 2 d
after transduction to selection with 1 lg/ml puromycin, whereas cells
transduced with pBabe-Hygro-p53Cter and pBabe-Hygro-SVLT
retrovirus were subjected to selection with 200 lg/ml hygromycin B
(Invitrogen). Retroviruses encoding the human papillomavirus
oncogenes E6 and E7 (pLXSN-E6/E7) were produced as described
earlier [58], and 2 d after transduction cells were subjected to
selection with 700 lg/ml G418.
To construct CDK-silencing lentiviruses, shRNA-oligos to CDK2
(59-GATCCGCACGTACGGAGTTGTGTATTCAAGAGATACA-
CAACTCCGTACGTGCCCTTTTTTGGAAA-39), CDK4 (59-
GATCCGCACTTACACCCGTGGTTGTTTCAAGAGAACAACCAC-
GGGTGTAAGTGCCTTTTTTGGAAA-39), CDK6 (59-GATCCGAG-
TAGTGCATCGCGATCTTTCAAGAGAAGATCGCGATGCAC-
TACTCGGTTTTTTGA-39), and a noncoding, random sequence
(Scramble; 59-ATCCGTTCTCCGAACGTGTCACGTTTCAAGA-
GAACGTGACACGTTCGGAGAATTTTTTGGAAA-39) were recom-
bined from the pENTR-H1-BgH- vector (provided by the
Biocentrum Helsinki SYSBIO initiative) by Gateway cloning technol-
ogy (Invitrogen) into the lentiviral vector pDSL_hpUGIH (LGC
Promochem, http://www.lgcpromochem.com/) according to the man-
ufacturer’s protocol. Viruses were produced by transfecting Invitro-
gen ViraPower viral packaging plasmids with pDSL_hpUGIH into
293FT cells with Lipofectamine 2000 reagent according to the
manufacturer’s protocol (Invitrogen). Lentiviral supernatants were
collected 72 h after transfection, ﬁltered through a 0.45-lm ﬁlter, and
used for spin transduction of EA.hy926 cells as described above.
Transduced cells were subjected for selection 72 h after transduction
with 50 lg/ml hygromycin.
rKSHV.219 production and infection. Infectious recombinant
KSHV virus (rKSHV.219) was produced from Vero cells latently
infected with rKSHV.219 (a kind gift from J. Vieira, University of
Washington, Seattle, Washington, United States), as described in [36].
hT-HDMECs, hT-HDMECs-p53CTer, hT-HDMECs-SVLT, or hT-
HDMECs-E6/E7 were plated 1 d before, and were infected by the
rKSHV.219 virus supernatant by spin-infection as described above
for spin-transduction. At 2 d after infection, the cells were subjected
to selection with 1 lg/ml puromycin.
Supporting Information
Figure S1. DNA Damage Response in v-Cyclin–Expressing Primary
HDMECs
(A) Cells were transduced with v-cyclin–encoding retrovirus (KpBMN)
and grown on coverslips for 3 d. Transduced cells were stained with
antibodies against pS-ATM, pT-Chk2, and 53BP1 as indicated in the
ﬁgure. The left panels show GFP expressed from the retrovirus. Scale
bar ¼ 20 lm.
Found at doi:10.1371/journal.ppat.0030140.sg001 (1.8 MB TIF).
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DNA Damage Response in KS TumorigenesisFigure S2. Proliferation of the Late KSHV-ECs Is Accompanied by an
Increase in LANA Signal
(A) hT-HDMECs were infected with rKSHV.219 virus and grown for 6
d (early) or approximately 10 wk (late). Proliferation of these cells in
relation to noninfected cells was determined by the MTT assay during
a 5-d period.
(B) KSHV-ECs grown for 8 d after infection (early) or for 10 wk (late).
Infected cells were labeled with anti-LANA antibodies (red) and
Hoechst (blue). Quantitation for cells with more than 11 dots of
LANA is indicated in the graph. Scale bar ¼ 20 lm.
Found at doi:10.1371/journal.ppat.0030140.sg002 (589 KB TIF).
Figure S3. p53-Dependent Apoptosis Is Restrained in KSHV-Infected
Endothelial Cells
Late, post-crisis KSHV-ECs and their passage-matched, parental,
noninfected ECs were treated with 7 lM Nutlin-3a. Cell viability was
determined by trypan blue exclusion, and the percentage of dead
cells was determined at 24, 48, and 96 h after the treatment. The
values represent the percentage of apoptotic cells relative to the
vehicle-treated control (i.e., percentage of apoptotic cells in vehicle-
treated sample was subtracted from the percentage of apoptotic cells
induced by Nutlin-3a).
Found at doi:10.1371/journal.ppat.0030140.sg003 (299 KB TIF).
Figure S4. DNA Damage Response Is Activated in Early-Stage KS
Lesions
(A) Parafﬁn-embedded sections of early-stage (Patch) and late-stage
(Nodular) KS skin tumors were stained for pT-Chk2, and nuclei were
counterstained with Hoechst 33342.
(B) Early-stage (Patch) and late-stage (Nodular) KS skin lesions were
stained for c-H2AX, and nuclei were counterstained with Hoechst
33342. Arrows indicate inﬁltrated red blood cells. The rightmost
panels display magniﬁcations of a marked area indicated by a yellow
frame.
Images were captured at 203 and 403 magniﬁcation as indicated.
Scale bars ¼ 50 lM.
Found at doi:10.1371/journal.ppat.0030140.sg004 (6.1 MB TIF).
Figure S5. Speciﬁcity of the pT-Chk2 Staining
Parafﬁn-embedded sections of early-stage KS skin tumors were
stained with pT-Chk2 untreated (top panels) or pretreated with a
peptide speciﬁc for the Thr68 phosphorylation site (bottom panels).
The nuclei were counterstained with Hoechst 33342. Images were
captured at 203 magniﬁcation. Scale bar ¼ 50 lM.
Found at doi:10.1371/journal.ppat.0030140.sg005 (3.9 MB TIF).
Text S1. Supplemental Materials and Figure Legends
Found at doi:10.1371/journal.ppat.0030140.sd001 (219 KB DOC).
Supporting Information
Accession Numbers
The Genbank (http://www.ncbi.nlm.nih.gov/Genbank/) accession num-
bers for the genes and gene products discussed in this paper are ATM
(NM 000051), ATR (NM 001184), Cdc6 (NM 001254), Cdc25A (NM
001789), CDK1 (NM 033379), CDK2 (NM 001798), CDK4 (NM 000075),
CDK6 (NM 001259), Chk2 (NM 007194), cyclin B1 (NM 031966), cyclin
D3 (NM 001760), cyclin E (NM 001238), E2F1 (NM 005225), E1A
(AY147066), histone H2 (XM 636495), histone H3 (NM 003493), hTERT
(NM 198253), human papillomavirus E6 (EF424414), human papil-
lomavirus E7 (AF478148), K-Ras (M54968), LANA (AF305694), Myc
(NM 012333), Orc 1 (U40152), pRb (AF109873), p21Cip1 (NM 000389),
p27Kip1 (NM 004064), p53 (NM 000546), SV40 large T antigen
(AF168998), v-cyclin (U79416), vFLIP (U90534), and 53BP1 (NM
005657).
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